Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Coherus Biosciences (CHRS)
NASDAQ:CHRS
Holding CHRS?
Track your performance easily
CHRS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.01 - $4.73
Previous Close$1.05
Volume2.83M
Average Volume (3M)1.90M
Market Cap
$120.97M
Enterprise Value$189.28M
Total Cash (Recent Filing)$159.24M
Total Debt (Recent Filing)$227.56M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Nov 04, 2024EPS Estimate
-$0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding115,208,583
10 Day Avg. Volume2,460,900
30 Day Avg. Volume1,897,760
Standard Deviation0.17
R-Squared0.04
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-1.55
Price to Sales (P/S)0.39
Price to Cash Flow (P/CF)0.50
P/FCF Ratio0.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.61
Enterprise Value/Gross Profit1.93
Enterprise Value/Ebitda15.45
Forecast
1Y Price Target
$7.13Price Target Upside530.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Coherus Biosciences News
PremiumCompany Announcements
Coherus Biosciences Manages UDENYCA Supply Interruption and Cost Reductions
PremiumCompany Announcements
Coherus Biosciences Appoints Bryan McMichael as CFO
Bulls Say, Bears Say
Bulls Say
Market PositioningThe three presentation options for Udenyca differentiate it from other pegfilgrastim biosimilar manufacturers as well as the originator Amgen's Neulasta franchise.
Product InnovationUdenyca has been growing nicely in recent quarters due to the introduction of the on-body device and autoinjector, which has led to share gains.
Sales PerformanceCoherus reported 2Q24 results, including better-than-expected Udenyca sales driving a top-line beat.
Bears Say
Management StrategyManagement's lack of commitment to cash flow positivity in 2024 could weigh on the stock.
Market PerformancePricing deterioration has worsened with ~ -40% to -70% y/y declines in 1Q and 2Q of 2024 for Udenyca.
Supply Chain IssuesThe company disclosed that its U.S.-based Contract Manufacturing Organization for final packaging informed the company of its over-commitments and capacity constraints, causing a temporary Udenyca supply interruption.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CHRS FAQ
What was Coherus Biosciences’s price range in the past 12 months?
Coherus Biosciences lowest stock price was $1.01 and its highest was $4.73 in the past 12 months.
What is Coherus Biosciences’s market cap?
Currently, no data Available
When is Coherus Biosciences’s upcoming earnings report date?
Coherus Biosciences’s upcoming earnings report date is Nov 04, 2024 which is in 45 days.
How were Coherus Biosciences’s earnings last quarter?
Coherus Biosciences released its earnings results on Aug 08, 2024. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.249 by $0.139.
Is Coherus Biosciences overvalued?
According to Wall Street analysts Coherus Biosciences’s price is currently Undervalued.
Does Coherus Biosciences pay dividends?
Coherus Biosciences does not currently pay dividends.
What is Coherus Biosciences’s EPS estimate?
Coherus Biosciences’s EPS estimate is -$0.16.
How many shares outstanding does Coherus Biosciences have?
Coherus Biosciences has 115,208,580 shares outstanding.
What happened to Coherus Biosciences’s price movement after its last earnings report?
Coherus Biosciences reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.249. Following the earnings report the stock price went up 10.853%.
Which hedge fund is a major shareholder of Coherus Biosciences?
Among the largest hedge funds holding Coherus Biosciences’s share is Woodline Partners LP. It holds Coherus Biosciences’s shares valued at 558K.
---
Coherus Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.13 (530.97% Upside)
$7.13 (530.97% Upside)
Blogger Sentiment
Bullish
CHRS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 219.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.82%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
43.71%
Trailing 12-Months
Company Description
Coherus Biosciences
Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
---
CHRS Earnings Call
Q2 2024
0:00 / 0:00
---
CHRS Stock 12 Month Forecast
Average Price Target
$7.13
▲(530.97% Upside)
Technical Analysis
Best Analysts Covering CHRS
1 Year
1 Year Success Rate
2/23 ratings generated profit
1 Year Average Return
-38.61%
reiterated a buy rating last month
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 8.70% of your transactions generating a profit, with an average return of -38.61% per trade.
---